Cyclooxygenase-2 Inhibitors: A Painful Lesson
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) represent a clinically important class of agents. NSAIDs are commonly used in treatment of conditions such as headache, fever, inflammation and joint pain. Complications often arise from chronic use of NSAIDs. Gastrointestinal (GI) toxicity in the form of gastritis, peptic erosions and ulcerations and GI bleeds limit usage of NSAIDs. These toxicities are thought to be due to cyclooxygenase (COX)-1 blockade. COX-1 generates cytoprotective prostanoids such as prostaglandin (PG) E2 and prostacyclin (PGI2). COX-2 inhibitors, commonly referred to as coxibs, were developed to inhibit inflammatory prostanoids without interfering with production of COX-1 prostanoids. Concerns over cardiovascular safety, however, have evolved based on the concept of inhibition of COX-2-derived endothelial prostanoids without inhibition of platelet thromboxane A2, leading to increased cardiovascular risk. The Celecoxib Long-Term Arthritis Safety Study (CLASS) trial did not show a significant increase in cardiovascular risk for celecoxib (Celebrex), but results of the Vioxx Gastrointestinal Outcomes Research (VIGOR) study showed an increased cardiovascular risk with long-term daily usage of rofecoxib in patients with rheumatoid arthritis. The Adenomatous Poly Prevention on Vioxx (APPROVe) trial further evaluated cardiovascular effects of rofecoxib and recently led to removal of this drug from the marketplace. Coxibs affect renal function via blockade of normal COX-2 functions. COX-2 expression increases in high renin states and in response to a high-sodium diet or water deprivation. PGI2 and PGE2 are the most important renal prostanoids. PGI2 inhibition results in hyperkalemia. PGE2 inhibition results in sodium retention, which leads to hypertension, peripheral edema and potentially exacerbation of heart failure. This review article discusses beneficial and deleterious effects associated with prostanoids produced by COX-1 and COX-2 in various organs and how blockade of these products translates into clinical medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519 · cited 1×
“The cardiovascular risk was detected only after a much longer time of drug exposure than previous trials [158].”
ResultCOX-3: in the wrong frame in mind
Dinchuk, J. E., Liu, R. Q., & Trzaskos, J. M. (2003) · Immunology Letters · doi:10.1016/s0165-2478(02)00268-7 · Cited by 100 · cited 1×
“However, an acetaminophen-sensitive COX-3 protein is not expressed in humans and rodents because retention of intron-1 results in a frame-shift in messenger RNA that leads to production of a truncated protein with a completely different amino acid sequence than COX-1 or COX-2 [15].”
Background
Cited by
Physiology and neurobiology of stress and adaptation: central role of the brain
McEwen, B. S. (2007) · Physiological Reviews · doi:10.1152/physrev.00041.2006 · Cited by 5,429
McEwen, B. S., & Gianaros, P. J. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05331.x · Cited by 1,715
Annunziata, F., Pinna, C., Dallavalle, S., Tamborini, L., & Pinto, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134618 · Cited by 491
Rishton, G. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.007 · Cited by 276
Pathophysiological role of prostaglandin E synthases in liver diseases
Xu, D., Cai, J., Wan, Z.-K., Gao, H., & Sun, Y. (2021) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2021.106552 · Cited by 10
Metadata
- Authors
- Sanghi, S., MacLaughlin, E., Jewell, C., Chaffer, S., Naus, P., Watson, L., & Dostal, D.
- Venue
- Cardiovascular & Hematological Disorders-Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-06-01
- Volume
- 6
- Issue
- 2
- Pages
- 83-98
- ISSN
- 1568-0061 (ISSN-L)
- 1871-529X
- OpenAlex
- W2006228380
- Cited by
- 73
- References
- 2
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclooxygenase-2 Inhibitors: A Painful Lesson. https://app.cochat.ai/papers/10.2174/187152906777441803
- The paper
- Sanghi, S., MacLaughlin, E., Jewell, C., Chaffer, S., Naus, P., Watson, L., & Dostal, D. (2006). Cyclooxygenase-2 Inhibitors: A Painful Lesson. Cardiovascular & Hematological Disorders-Drug Targets. https://doi.org/10.2174/187152906777441803
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.